Stocks News

LAST PRICE
283.7300
TODAY'S CHANGE (%)
Trending Down-18.9400 (-6.2576%)

Bid / Lots
283.7200/ 7
Ask / Lots
285.4400/ 7
Open / Previous Close
303.2900 / 302.6700
Day Range
Low 281.7100
High 303.2900
52 Week Range
Low 154.8130
High 368.2900
Volume
255,140
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 6, 2024
- Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
  
  CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
- Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing, from 3:28AM ET on Wednesday Nov 06, 2024 by MT Newswires
  3:28AM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: MDGL
  03:28 AM EST, 11/06/2024 (MT Newswires) -- Richard S Levy, Director, on November 01, 2024, sold 5,000 shares in Madrigal Pharmaceuticals (MDGL) for $1,504,703. Following the Form 4 filing with the SEC, Levy has control over a total of 11,012 shares ...
Nov 5, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 11:22AM ET on Tuesday Nov 05, 2024 by Dow Jones
  11:22AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 11:22 ET (16:22 GMT)
- B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating, from 9:14AM ET on Tuesday Nov 05, 2024 by MT Newswires
  9:14AM ET on Tuesday Nov 05, 2024 by MT Newswires
  Companies Mentioned: MDGL
  09:14 AM EST, 11/05/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average outperform rating and price target range of $155 to $530, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic resea...
Nov 1, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Buy by UBS, from 2:37PM ET on Friday Nov 01, 2024 by Dow Jones
  2:37PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 01, 2024 14:37 ET (18:37 GMT)

Yesterday
- Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX), from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 19 hours ago by Dow Jones
  19 hours ago by Dow Jones
  Companies Mentioned: VKTX
- VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money, from 7:31AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:31AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: VKTX
Nov 13, 2024
- Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing, from 7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires
  7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: CYTK
- DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: RNA
- DJ Nuvalent Is Maintained at Outperform by BMO Capital, from 8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: NUVL
- DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones
  5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: RNA
Nov 12, 2024
- Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire
  4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: VKTX
- Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: VKTX
- Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference, from 4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones
  4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CYTK

Madrigal Pharmaceuticals Inc
NASDAQ:MDGLUnited States

Search Criteria

Nov 6, 2024

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing, from 3:28AM ET on Wednesday Nov 06, 2024 by MT Newswires

Nov 5, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 11:22AM ET on Tuesday Nov 05, 2024 by Dow Jones

B. Riley Adjusts Price Target on Madrigal Pharmaceuticals to $236 From $194, Maintains Neutral Rating, from 9:14AM ET on Tuesday Nov 05, 2024 by MT Newswires

Nov 1, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Buy by UBS, from 2:37PM ET on Friday Nov 01, 2024 by Dow Jones

Peers Headlines

Yesterday

Viking Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viking Therapeutics, Inc. (VKTX), from 18 hours ago by Dow Jones

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX, from 19 hours ago by Dow Jones

VKTX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Viking Therapeutics, Inc. Shareholders Who Lost Money, from 7:31AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing, from 7:10PM ET on Wednesday Nov 13, 2024 by MT Newswires

DJ Avidity Biosciences Is Maintained at Buy by Chardan Capital, from 6:40PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Nuvalent Is Maintained at Outperform by BMO Capital, from 8:14AM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Avidity Biosciences Price Target Maintained With a $60.00/Share by Needham, from 5:07AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by PR Newswire

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting(R) 2024, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference, from 4:00PM ET on Tuesday Nov 12, 2024 by Dow Jones